CJEU puts further brakes on SPCs
Martyn Jandula / Shutterstock.com
The Court of Justice of the European Union’s (CJEU) recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates (SPC) last week has left some big questions unanswered.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
CJEU, Court of Justice of the European Union, SPC, supplementary protection certificate, Abraxis, marketing authorisation